Interestingly, a glucagon-like peptide-1 receptor (GLP-1R) agonist treatment significantly reversed multiply transcriptomic changes associated with AD in BECs, including reduced GLUT1 (Zhao et al., 2020). This evidence concerns the gene GLP1R and Alzheimer disease.